| Literature DB >> 20080889 |
George Sgouros1, John C Roeske, Michael R McDevitt, Stig Palm, Barry J Allen, Darrell R Fisher, A Bertrand Brill, Hong Song, Roger W Howell, Gamal Akabani, Wesley E Bolch, A Bertrand Brill, Darrell R Fisher, Roger W Howell, Ruby F Meredith, George Sgouros1, Barry W Wessels, Pat B Zanzonico.
Abstract
The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20080889 PMCID： PMC5680544 DOI： 10.2967/jnumed.108.058651
Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057